P271: Evolving Targets in Ulcerative colitis: Defining Disease Clearance in the VARSITY StudyECCO'21 VirtualYear: 2021
Authors: Danese, S.(1);Schreiber, S.(2);Loftus Jr., E.(3);Colombel, J.F.(4);Peyrin-Biroulet, L.(5);Agboton, C.(6);Lindner, D.(6);Lirio, R.(7);Sands, B.(4);
(1)Humanitas University, Department of Gastroenterology, Milan, Italy;(2)University Hospital Schleswig-Holstein, Clinic for Internal Medicine, Kiel, Germany;(3)Mayo Clinic College of Medicine, Department of Internal Medicine, Rochester MN, United States;(4)Icahn School of Medicine at Mount Sinai, Department of Gastroenterology, New York, United States;(5)Nancy University Hospital, Department of Gastroenterology, Nancy, France;(6)Takeda Pharmaceuticals, Takeda, Zurich, Switzerland;(7)Takeda Pharmaceuticals USA Inc, Takeda, Cambridge, United States
P272: Tofacitinib as salvage therapy for patients hospitalized with refractory severe active ulcerative colitis: a GETAID multicenter prospective/retrospective cohortECCO'21 VirtualYear: 2021
Authors: Uzzan, M.(1);Bresteau, C.(2);Laharie, D.(3);Stefanescu, C.(4);Carbonnel, F.(2);Serrero, M.(5);Viennot, S.(6);Nachury, M.(7);Amiot, A.(8);Altwegg, R.(9);Picon, L.(10);Nahon, S.(11);Vuitton, L.(12);Ah Soune, P.(13);Kirchgesner, J.(14);Peyrin-Biroulet, L.(15);Bouhnik, Y.(4);
(1)Hôpital Beaujon- APHP, Gastroenterology- IBD unit, Paris, France;(2)CHU Kremlin Bicêtre, Gastroenterology, Kremlin Bicetre, France;(3)CHU Bordeaux, Gastroenterology, Bordeaux, France;(4)Hopital Beaujon, Gastroenterology, Clichy, France;(5)Centre est Hôpital Nord, Gastroenterology, Marseille, France;(6)CHU Caen, Gastroenterology, Caen, France;(7)CHRU Lille, Gastroenterology, Lille, France;(8)Hopital Henri Mondor, Gastroenterology, Creteil, France;(9)CHU Montpellier, Gastroenterology, Montpellier, France;(10)CHU Tours, Gastroenterology, Tours, France;(11)CH Montfermeil, Gastroenterology, Montfermeil, France;(12)CHU Besancon, Gastroenterology, Besancon, France;(13)CH Toulon, Gastroenterology, Toulon, France;(14)Hopital Saint Antoine- APHP, Gastroenterology, Paris, France;(15)CHRU Nancy, Gastroenterology, Nancy, France
P273: The duration of clinical remission in patients with Crohn's disease depends on the frequency of administration of mesenchymal stromal cells of the bone marrowECCO'21 VirtualYear: 2021
Authors: Knyazev, O.(1,2,3);Kagramanova, A.V.(1);Lishchinskaya, A.(1);Li, I.(1);Shkurko, T.(2);Veselov, A.(2);Fadeeva, N.(4);Zhulina, E.(4);Parfenov, A.(1);
(1)Moscow Clinical Scientific Center named after A. S. Loginov, Department of IBD, Moscow, Russian Federation;(2)Research Institute of Health Organization and Medical Management, Organization of Coloproctology, Moscow, Russian Federation;(3)State Scientific Centre of Coloproctology named after A.N. Ryzhyh, Department of IBD, Moscow, Russian Federation;(4)Moscow Clinical Scientific Center named after A.S. Loginov, Department of IBD, Moscow, Russian Federation
P274: Drug utilization of biologic therapy in Crohn’s disease and ulcerative colitis: A population based Danish cohort study 2015-2018ECCO'21 VirtualYear: 2021
Authors: Jensen, K.(1);Jensen, C.B.(1);Wennerström, C.(2);Sommer, K.J.(3);Burisch, J.(4);Petersen, J.(1);
(1)Center for Clinical Research and Prevention- Frederiksberg Hospital, Copenhagen Phase IV Unit Phase4Cph, Frederiksberg, Denmark;(2)Janssen Cilag AB, Nordic Medical Operations, Solna, Sweden;(3)Janssen-Cilag A/S, Medical Affairs, Birkerød, Denmark;(4)Hvidovre Hospital, Gastrounit- Medical Division, Hvidovre, Denmark
P275: Course of COVID-19 in patients with Inflammatory Bowel Diseases treated with biologics: the Israeli experienceECCO'21 VirtualYear: 2021
Authors: Lichtenstein, L.(1);Koslowsky, B.(2);Avni-Biron, I.(3);Ovadia, B.(4);Ben-Bassat, O.(5);Naftali, T.(6);Kopylov, U.(7);Haberman, Y.(7);Banai Eran, H.(3);Eliakim, R.(7);Lahat-Zok, A.(7);Hirsch, A.(8);Zittan, E.(9);Maharshak, N.(8);Waterman, M.(10);Israeli, E.(11);Goren, I.(3);Ollech, J.E.(3);Yanai, H.(3);Ungar, B.(7);Avidan, B.(7);Ben Hur, D.(12);Melamud, B.(11);Segol, O.(12);Shalem, Z.(13);Dotan, I.(3);Odes, S.H.(14);Ben-Horin, S.(7);Snir, Y.(3);Milgrom, Y.(15);Broide, E.(13);Goldin, E.(2);Delgado, S.(1);Ron, Y.(8);Cohen, N.A.(8);Maoz, E.(16);Zborovski, M.(17);Odeh, S.(18);Abu Freha, N.(19);Bar-Gil Shitrit, A.(2);
(1)Assuta Medical Center, Gastroenterology, Ashdod, Israel;(2)Shaare Zedek Medical Center, Digestive Diseases Institute, Jerusalem, Israel;(3)Rabin Medical Center, Division of Gastroenterology, Petah Tikva, Israel;(4)Hillel Yaffe Medical Center, Gastroenterology, Hadera, Israel;(5)Barzilai Medical Center, Gastroenterology, Ashkelon, Israel;(6)Meir Medical Center, Gastroenterology, Kfar Saba, Israel;(7)The Chaim Sheba Medical Center, Gastroenterology, Tel Hashomer, Israel;(8)Tel Aviv Sourasky Medical Center Ichilov, Gastroenterology, Tel Aviv, Israel;(9)Ha`emek Medical Center, Gastroenterology, Afula, Israel;(10)Rambam Medical Center, Gastroenterology, Haifa, Israel;(11)Wolfson Medical Center, Gastroenterology, Holon, Israel;(12)Lady Davis Carmel Medical Center, Gastroenterology, Haifa, Israel;(13)Shamir Medical Center Assaf Harofeh, Gastrenterology, Be'er Ya'akov, Israel;(14)Mayanei HaYeshua Medical Center, Gastroenterology, Bnei Brak, Israel;(15)Hadassah Medical Center, Gastroenterology, Jerusalem, Israel;(16)Clalit Health Services, Gastroenterology, Tel Aviv, Israel;(17)Clalit Health Cervices, Gastoenterology, Ashdod, Israel;(18)Bnei Zion, Gastroenterology, Haifa, Israel;(19)Soroka Medical Center, Gastroenterology, Beer Sheva, Israel; and Eyal Shachar Yehuda Chowers Tal Engel Hila Reiss Arie Segal Adar Zinger On behalf of the Israeli IBD society
P276: Influence of vedolizumab on extraintestinal manifestations in Inflammatory Bowel Disease: a nationwide multicenter study of the GETECCU Eneida registryECCO'21 VirtualYear: 2021
Authors: Pérez Galindo, P.(1);Gisbert, J.P.(2);Carrillo-Palau, M.(3);Bertoletti, F.(4);González-Vivó, M.(5);Ferrer, J.A.(6);Pajares, R.(7);Merino, O.(8);Castaño, A.(9);Chaparro, M.(2);Calvo, M.(10);Barreiro-de-Acosta, M.(11);Rodríguez, A.(12);Lorente, R.H.(13);Algaba, A.(14);Riado, D.(6);Vela, M.(15);De-la-Maza, S.(16);Llaó, J.(17);Vega, P.(18);Utrilla, A.(19);Almela, P.(20);Carpio, D.(1);
(1)Complexo Hospitalario Universitario de Pontevedra, Servicio de Aparato Digestivo, Pontevedra, Spain;(2)Hospital Universitario de La Princesa- Instituto de Investigación Sanitaria Princesa IIS-IP- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBEREHD, Servicio de Aparato Digestivo, Madrid, Spain;(3)Hospital Universitario de Canarias, Servicio de Aparato Digestivo, Tenerife, Spain;(4)Hospital de la Santa Creu i Sant Pau, Servicio de Aparato Digestivo, Barcelona, Spain;(5)Hospital del Mar, Servicio de Aparato Digestivo, Barcelona, Spain;(6)Hospital Universitario Fundación Alcorcón, Servicio de Aparato Digestivo, Alcorcón, Spain;(7)Hospital Universitario Infanta Sofía, Servicio de Aparato Digestivo, San Sebastián de los Reyes, Spain;(8)Hospital Universitario Cruces, Servicio de Aparato Digestivo, Baracaldo, Spain;(9)Hospital Universitario Central de Asturias, Servicio de Aparato Digestivo, Oviedo, Spain;(10)Hospital Universitario Puerta de Hierro, Servicio de Aparato Digestivo, Majadahonda, Spain;(11)Hospital Clínico Universitario de Santiago de Compostela, Servicio de Aparato Digestivo, Santiago de Compostela, Spain;(12)Hospital General Universitario de Alicante, Servicio de Aparato Digestivo, Alicante, Spain;(13)Hospital General Universitario de Ciudad Real, Servicio de Aparato Digestivo, Ciudad Real, Spain;(14)Hospital Universitario de Fuenlabrada, Servicio de Aparato Digestivo, Fuenlabrada, Spain;(15)Hospital Universitario Nuestra Señora de Candelaria, Servicio de Aparato Digestivo, Tenerife, Spain;(16)Hospital Universitario de Basurto, Servicio de Aparato Digestivo, Bilbao, Spain;(17)Althaia Xarxa Assistencial Universitària de Manresa, Servicio de Aparato Digestivo, Manresa, Spain;(18)Complexo Hospitalario Universitario de Ourense, Servicio de Aparato Digestivo, Ourense, Spain;(19)Hospital General San Jorge, Servicio de Aparato Digestivo, Huesca, Spain;(20)Hospital General Universitario de Castellón, Servicio de Aparato Digestivo, Castellón, Spain
P278: Type IV collagen formation/degradation ratio predicts response to infliximab induction therapy in patients with Ulcerative ColitisECCO'21 VirtualYear: 2021
Authors: Bourgonje, A.R.(1);Alexdottir, M.(2);Loveikyte, R.(1);Bay-Jensen, A.C.(2);van Dullemen, H.M.(1);Visschedijk, M.C.(1);Festen, E.A.M.(1);Weersma, R.K.(1);Karsdal, M.A.(2);Faber, K.N.(1);Mortensen, J.H.(2);Dijkstra, G.(1);
(1)University of Groningen- University Medical Center Groningen, Gastroenterology and Hepatology, Groningen, The Netherlands;(2)Nordic Bioscience, Biomarkers and Research, Herlev, Denmark
P279: Potential of managed care programmes for patients with inflammatory bowel diseases – results from a large survey study among physicians and IBD-patients in Germany, Austria and Switzerland (the EASEIBD study)ECCO'21 VirtualYear: 2021
Authors: Bokemeyer, B.(1);Kaiser, C.(2);Primas, C.(3);Novacek, G.(3);Biedermann, L.(4);Seibold, F.(5);Tappe, U.(6);Bettenworth, D.(7);Graw, J.(2);Hartmann, P.(8);Plachta-Danielzik, S.(9);Schultz, C.(2);
(1)Interdisziplinäres Crohn Colitis Center Minden und Medizinische Klinik I- Universitätsklinik Schleswig-Holstein- Campus Kiel, Gastroenterologische Praxis Minden, Minden, Germany;(2)Institut für Innovationsforschung, Lehrstuhl für Technologiemanagement- Christian-Albrechts-Universität zu Kiel, Kiel, Germany;(3)Medizinische Universitätsklinik Wien, Universitätsklinik für Innere Medizin III, Vienna, Austria;(4)Universitätsspital Zürich, Klinik für Gastroenterologie und Hepatologie, Zürich, Switzerland;(5)Gastroenterologische Praxis, Crohn-Colitis-Zentrum, Bern, Switzerland;(6)Gastroenterologische Gemeinschaftspraxis, Innere Medizin II- St. Barbara-Klinik Hamm, Hamm, Germany;(7)Praxis für Innere Medizin Münster, CED-Schwerpunktpraxis, Münster, Germany;(8)Gastroenterologische Gemeinschaftspraxis Minden, Fachgesellschaft für Asssitenzpersonal CED - FA-CED, Minden, Germany;(9)Kompetenznetz Darmerkrankungen, Studienabteilung, Kiel, Germany
P280: Introduction of subcutaneous infliximab CT-P13 and vedolizumab in daily clinical practice: outstanding questions demonstrate the need for post-marketing studiesECCO'21 VirtualYear: 2021
Authors: Ferrante, M.(1,2);Sabino, J.(1,2);Lobaton, T.(3);Dreesen, E.(4);Hoefkens, E.(5);Fierens, L.(2);Liefferinckx, C.(6);
(1)University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium;(2)Catholic University of Leuven, Department of Chronic Diseases- Metabolism and Ageing, Leuven, Belgium;(3)University Hospital Ghent, Department of Gastroenterology, Ghent, Belgium;(4)Catholic University of Leuven, Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium;(5)Imelda General Hospital, Department of Gastroenterology, Bonheiden, Belgium;(6)Erasme Hospital ULB, Department of Gastroenterology, Brussels, Belgium
P281: Evaluation of trough level and disease activity after switch from adalimumab originator to biosimilar in patients with Inflammatory Bowel DiseaseECCO'21 VirtualYear: 2021
Authors: Deprez, N.(1);De Somer, T.(2);Baert, D.(2);Deceuninck, M.(3);Huys, I.(2);Mattens, V.(4);Sterckx, A.(4);Vanden Branden, S.(4);Vanderstraeten, E.(2);Vandervoort, J.(4);Vanheddegem, N.(2);Dewint, P.(2);
(1)UZ GENT, Gastroenterology, Tielt, Belgium;(2)AZ Maria Middelares, Gastroenterology, Gent, Belgium;(3)AZ Sint Vincentius Deinze, Gastroenterology, Deinze, Belgium;(4)OLV Aalst, Gastroenterology, Aalst, Belgium
P282: High plasma oncostatin-M predicts non-response to tumour necrosis factor-alpha antagonists in inflammatory bowel diseaseECCO'21 VirtualYear: 2021
Authors: Guo, A.(1);Ross, C.(2);Chande, N.(3);Gregor, J.(3);Ponich, T.(3);Beaton, M.(3);Khanna, R.(3);Kim, R.(4);Wilson, A.(5);
(1)Western University, Health Sciences, London, Canada;(2)Western University, Clinical Pharmacology, London, Canada;(3)London Health Sciences Centre, Gastroenterology, London, Canada;(4)London Health Sciences Centre, Clinical Pharmacology, London, Canada;(5)London Health Sciences Centre, Department of Gastroenterology, London, Canada
P283: Decrease in bowel wall thickness at intestinal ultrasound accurately detects early endoscopic remission and improvement in ulcerative colitis patients on tofacitinib: a longitudinal prospective cohort study.ECCO'21 VirtualYear: 2021
Authors: de Voogd, F.(1);Van Wassenaer, E.(2);Mookhoek, A.(3);Bots, S.(1);Van Gennep, S.(1);Duijvestein, M.(1);Ponsioen, C.(1);Löwenberg, M.(1);D'Haens, G.(1);Gecse, K.(1);
(1)Amsterdam UMC- Amsterdam Medical Center- University of Amsterdam, Department of Gastroenterology and Hepatology, Amsterdam, The Netherlands;(2)Amsterdam University Medical Center- Emma Children's Hospital- University of Amsterdam, Pediatric Gastroenterology-, Amsterdam, The Netherlands;(3)Amsterdam UMC- VU Medical Center- VU University, Department of Pathology, Amsterdam, The Netherlands
P284: Drug survival and remission rates in ustekinumab treated ulcerative colitis: Results from the Swedish Inflammatory Bowel Disease register (SWIBREG)ECCO'21 VirtualYear: 2021
Authors: Thunberg, J.(1);Björkqvist, O.(1);Olén, O.(2);Ludvigsson, J.F.(3);Eriksson, C.(1);Halfvarson, J.(1);
(1)Örebro University, School of Medical Sciences, Örebro, Sweden;(2)Karolinska Institutet, Department of Medicine, Stockholm, Sweden;(3)Karolinska Institutet, Department of Medical Epidemiology and Biostatistics, Stockholm, Sweden; SWIBREG study group
P285: A retrospective observational study on the effectiveness and safety of vedolizumab with or without budesonide induction therapy among patients with moderate-to-severe Crohn’s diseaseECCO'21 VirtualYear: 2021
Authors: Weisshof, R.(1);Vavricka, S.(2,3);Pouillon , L.(4);Braegger, F.(5);Roset, M.(6);Bent-Ennakhil, N.(5);Ferrante, M.(7);
(1)Rambam Healthcare Campus, Department of Gastroenterology, Haifa, Israel;(2)University Hospital Zürich, Department of Gastroenterology and Hepatology, Zürich, Switzerland;(3)Center for Gastroenterology and Hepatology AG, Center for Gastroenterology and Hepatology AG, Zürich, Switzerland;(4)Imeldaziekenhuis Bonheiden, Imelda GI Clinical Research Center, Bonheiden, Belgium;(5)Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals International AG, Glattpark-Opfikon, Switzerland;(6)IQVIA, Real World Solutions, Barcelona, Spain;(7)University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium
P286: Ustekinumab for Crohn’s Disease: Two-Year Results of the Initiative on Crohn and Colitis (ICC) Registry, a Nationwide Prospective Observational Cohort StudyECCO'21 VirtualYear: 2021
Authors: Straatmijer, T.(1);Biemans, V.B.C.(1);Hoentjen, F.(2);de Boer, N.K.H.(3);Bodelier, A.G.(4);Dijkstra, G.(5);van Dop, W.(2);Haans, J.J.L.(6);Jansen, J.M.(7);Maljaars, P.W.J.(8);van der Marel, S.(9);Oldenburg, B.(10);Ponsioen, C.Y.(11);Visschedijk, M.C.(5);de Vries , A.C.(12);West, R.(13);van der Woude, C.J.(12);Pierik, M.(6);Duijvestein, M.(11);van der Meulen- de Jong, A.E.(8);
(1)Initiative on Crohn and Colitis, Department of Gastroenterology and Hepatology, Amsterdam, The Netherlands;(2)Radboud University Medical Centre, Department of Gastroenterology and Hepatology, Nijmegen, The Netherlands;(3)Amsterdam University Medical Centre- Vrije Universiteit Amsterdam- Amsterdam Gastroenterology Endocrinology Metabolism AGEM Research Institute, Department of Gastroenterology and Hepatology, Amsterdam, The Netherlands;(4)Amphia hospital, Department of Gastroenterology and Hepatology, Breda, The Netherlands;(5)University Medical Centre Groningen- University of Groningen, Department of Gastroenterology and Hepatology, Groningen, The Netherlands;(6)Maastricht University Medical Centre, Department of Gastroenterology and Hepatology, Maastricht, The Netherlands;(7)Onze Lieve Vrouwe Gasthuis, Department of Gastroenterology and Hepatology, Amsterdam, The Netherlands;(8)Leiden University Medical Centre, Department of Gastroenterology and Hepatology, Leiden, The Netherlands;(9)Haaglanden Medisch Centre, Department of Gastorenterology and Hepatology, The Hague, The Netherlands;(10)University Medical Centre Utrecht, Department of Gastroenterology and Hepatology, Utrecht, The Netherlands;(11)Amsterdam UMC- University of Amsterdam- Amsterdam Gastroenterology Endocrinology Metabolism AGEM Research Institute, Department of Gastroenterology and Hepatology, Amsterdam, The Netherlands;(12)Erasmus Medical Centre, Department of Gastroenterology and Hepatology, Rotterdam, The Netherlands;(13)Franciscus Gasthuis & Vlietland, Department of Gastroenterology and Hepatology, Rotterdam, The Netherlands
P288: Vedolizumab May Be An Effective Option For The Management Of Postoperative Recurrence Of Crohn’s DiseaseECCO'21 VirtualYear: 2021
Authors: Macaluso, F.S.(1);Cappello, M.(2);Crispino, F.(2);Grova, M.(2);Privitera, A.C.(3);Piccillo, G.(3);Magnano, A.(4);Ferracane, C.(4);Belluardo, N.(5);Giangreco, E.(5);Fries, W.(6);Viola, A.(6);Di Mitri, R.(7);Mocciaro, F.(7);Camilleri, S.(8);Garufi, S.(8);Renna, S.(1);Casà, A.(1);Maida, M.(8);Orlando, A.(1);
(1)Ospedali Riuniti Villa Sofia-Cervello, Department of Medicine, Palermo, Italy;(2)University of Palermo, Gastroenterology & Hepatology Section- Promise-, Palermo, Italy;(3)“Cannizzaro” Hospital, Inflammatory Bowel Disease Unit, Catania, Italy;(4)“Vittorio Emanuele” Hospital, Gastroenterology Unit, Catania, Italy;(5)“Guzzardi” Hospital, Gastroenterology Unit, Vittoria, Italy;(6)'G. Martino” Hospital, Inflammatory bowel disease Unit, Messina, Italy;(7)“ARNAS Civico - Di Cristina – Benfratelli” Hospital, Gastroenterology and Endoscopy Uni, Palermo, Italy;(8)“S. Elia- Raimondi” Hospital, Gastroenterology and Endoscopy Unit-, Caltanissetta, Italy Sicilian Network for Inflammatory Bowel DIseases (SN-IBD)
P289: A French nationwide prospective study on patients with Crohn’s disease and ulcerative colitis treated with Infliximab-biosimilar CT-P13 in a real-life setting: two-year follow-up of the ReFLECT studyECCO'21 VirtualYear: 2021
Authors: Bouhnik, Y.(1);Nancey, S.(2);Assing, M.(3);Mammar, N.(3);Laharie, D.(4);
(1)CHU Beaujon, Gastroenterology, Clichy, France;(2)CHU Lyon, Gastroenterology, Lyon, France;(3)Pfizer, Inflammation & Immunology, Paris, France;(4)CHU Bordeaux Haut-Lévêque Hospital, Gastroenterology, Pessac, France
P290: Impact of concomitant 5-aminosalicylic acid therapy on vedolizumab efficacy and safety in Inflammatory Bowel DiseaseECCO'21 VirtualYear: 2021
Authors: Ungaro, R.(1);Kadali, H.(2);Zhang, W.(3);Adsul, S.(4);Reinisch, W.(5);
(1)The Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, United States;(2)Takeda, Global Patient Safety and Evaluation, Cambridge, United States;(3)Takeda, Statistical and Quantitative Science, Cambridge, United States;(4)Takeda, Global Medical Affairs, Zurich, Switzerland;(5)Medical University of Vienna, Department of Internal Medicine III, Vienna, Austria
